Atypical antidepressants

Atypical antidepressants

Watch later

Watch later

Vascular tumors
DNA alkylating medications
Pediatric bone tumors: Clinical
Pediatric gastrointestinal bleeding: Clinical
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Fragile X syndrome
Huntington disease
Myotonic dystrophy
Friedreich ataxia
Klinefelter syndrome
Angelman syndrome
Prader-Willi syndrome
Cri du chat syndrome
Williams syndrome
Alport syndrome
Marfan syndrome
von Hippel-Lindau disease
Newborn management: Clinical
Atypical antidepressants
Acid reducing medications
Adrenergic antagonists: Alpha blockers
Cell wall synthesis inhibitors: Penicillins
Protein synthesis inhibitors: Aminoglycosides
Herpesvirus medications
Stevens-Johnson syndrome
Burns
Nonbenzodiazepine anticonvulsants
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Coagulation (secondary hemostasis)
Patau syndrome (Trisomy 13)
Hypothyroidism medications
Spina bifida
Persistent truncus arteriosus
Antimalarials
DNA synthesis inhibitors: Fluoroquinolones
Miscellaneous protein synthesis inhibitors
Ventricular septal defect
Monoamine oxidase inhibitors
Miscellaneous hypoglycemics
Endocarditis: Pathology review
Infective endocarditis: Clinical
Endocarditis
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Fatty acid oxidation
Echinocandins
Haemophilus ducreyi (Chancroid)
Urinary tract infections: Clinical
Movement of water between body compartments
Typical antipsychotics
Cholinomimetics: Indirect agonists (anticholinesterases)
Positive inotropic medications
cGMP mediated smooth muscle vasodilators
Aortic valve disease
Familial hypercholesterolemia
Cardiovascular system anatomy and physiology
Hemophilia
Antimetabolites for cancer treatment
Complement system
Topoisomerase inhibitors
Eye conditions: Inflammation, infections and trauma: Pathology review
Meningitis
Muscle spindles and golgi tendon organs
Ascending and descending spinal tracts
Trigeminal neuralgia
Hypokinetic movement disorders: Clinical
Cerebellum
Basal ganglia: Direct and indirect pathway of movement
Anatomy of the olfactory (CN I) and optic (CN II) nerves
Photoreception
Cholinergic receptors
Hemianopsia
Nervous system anatomy and physiology
Peripheral nervous system histology
Major depressive disorder
Congenital adrenal hyperplasia
Urinary incontinence: Pathology review
Acute respiratory distress syndrome
Anatomy of the abdominal viscera: Large intestine
Congenital gastrointestinal disorders: Pathology review
Somatosensory pathways
Jaundice: Pathology review
Influenza virus
Alveolar surface tension and surfactant
Abnormal heart sounds
Fetal circulation
Total anomalous pulmonary venous return
Anatomy of the anterolateral abdominal wall
Anthelmintic medications
Hernias: Clinical
Cerebrospinal fluid
Vestibulo-ocular reflex and nystagmus
Night terrors
Cannabis use disorder
Sympathetic nervous system
Cocaine use disorder
Complement deficiency
Brown-Sequard Syndrome
Bacillus cereus (Food poisoning)
Deep vein thrombosis and pulmonary embolism: Pathology review
Spinal muscular atrophy
Sleep disorders: Clinical
Lung cancer
Adult brain tumors
Polycystic kidney disease
Pulmonary hypoplasia
Sensitivity and specificity
Developmental milestones: Clinical
Lymphatic system anatomy and physiology
Shaken baby syndrome
Shigella
Beckwith-Wiedemann syndrome
Iron deficiency anemia
Vessels and nerves of the gluteal region and posterior thigh
Emotion
Antidiarrheals
Vascular dementia
Aspergillus fumigatus
Cryptococcus neoformans
Trichuris trichiura (Whipworm)
Multiple endocrine neoplasia
Growth hormone deficiency
Growth and development
Cartilage structure and growth
Pituitary adenoma
Coxsackievirus
Pediatric brain tumors
Gallbladder disorders: Pathology review
Gallbladder disorders: Clinical
Extracellular matrix
Ischemia
Vitamin K deficiency
Jaundice: Clinical
Prebiotics and probiotics
Nucleotide metabolism
Immune thrombocytopenia
Hyperlipidemia
Hypertriglyceridemia
Respiratory syncytial virus
Megaloblastic anemia
Fatty acid synthesis
Multiple myeloma
Waldenstrom macroglobulinemia
Systemic lupus erythematosus
Hypercalcemia
Strongyloides stercoralis
Polycythemia vera (NORD)
Hypokalemia
Metabolic alkalosis
Paracetamol toxicity
Chronic kidney disease
Myelofibrosis (NORD)
Age-related macular degeneration
Myeloproliferative neoplasms: Clinical
Metaplasia and dysplasia
Blood brain barrier
Epidural abscess
Cystinosis
Fat-soluble vitamin deficiency and toxicity: Pathology review
Zinc deficiency and protein-energy malnutrition: Pathology review
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Kidney stones
Pasteurella multocida
Mitosis and meiosis
Haemophilus influenzae
Escherichia coli
Cell membrane
Otitis externa
Primary ciliary dyskinesia
Rheumatic heart disease
Sjogren syndrome: Clinical
Attention deficit hyperactivity disorder
Neonatal ICU conditions: Clinical
Oncogenes and tumor suppressor genes
Muscular system anatomy and physiology
Polycystic ovary syndrome
Azoles
Brain abscess
Disease causality
Entamoeba histolytica (Amebiasis)
Bone tumors
Pediatric infectious rashes: Clinical
Lower back pain: Clinical
Antiphospholipid syndrome
Adrenal insufficiency: Pathology review
Dementia and delirium: Clinical
Eczematous rashes: Clinical
Pulmonary embolism
Syncope: Clinical
Pharyngeal arches, pouches, and clefts
Uterine disorders: Pathology review
Distal convoluted tubule
Antidiuretic hormone
Adrenal hormone synthesis inhibitors
Idiopathic intracranial hypertension
Clinical Skills: Body Temperature Assessment
Toxidromes: Clinical
Anxiolytics and sedative-hypnotics: Nursing pharmacology
Abuse, mistreatment, and neglect
Sensory system: Eye and ear disorders
Vaccinations: Clinical
Anatomy of the orbit
Clinical Skills: High-frequency oscillatory ventilation (HFOV)
Anxiety disorders: Clinical
Primary adrenal insufficiency
Hodgkin lymphoma
Sympatholytics: Alpha-2 agonists
Antidepressants - SSRIs and SNRIs: Nursing pharmacology
Antimetabolites for cancer treatment
Pediatric upper airway conditions: Clinical

Transcript

Watch video only

Atypical antidepressants are mainly used to treat major depressive disorder. This disorder causes a persistent feeling of sadness and loss of interest in everyday activities. Even though the exact cause of depression is still unknown, there's some evidence that suggests it’s related to low levels of neurotransmitters like serotonin, norepinephrine, and dopamine. Typical antidepressants like selective serotonin reuptake inhibitors or tricyclic antidepressants work by increasing the levels of serotonin and norepinephrine, while atypical antidepressants often have multiple mechanisms of action.

All right, now within the brain, there are many different types of neurons, but we’re going to focus only on three: serotonergic neurons, which produce serotonin; noradrenergic neurons, which produce norepinephrine; and dopaminergic neurons, which produce dopamine. Each of these neurons synthesizes and stores their neurotransmitters in small vesicles. So, when an action potential reaches the presynaptic membrane, these vesicles fuse with the membrane, releasing neurotransmitters into the synaptic cleft. Once released, serotonin (or 5-HT) binds to 5-HT2 receptors on the postsynaptic membrane, thereby increasing neural stimulation, and regulating mood, feeding, and reproductive behavior. On the other hand, norepinephrine binds to norepinephrine receptors on the postsynaptic membrane, boosting alertness. And finally, dopamine binds to dopamine receptors, thereby stimulating cognitive functions, motivation, and awakeness.

As long as there’s a high enough concentration of neurotransmitters in the synaptic cleft, the postsynaptic neurons will continue to fire. Now, serotonergic neurons on their presynaptic membrane have serotonin transporters (or SERT); noradrenergic neurons have norepinephrine transporters (or NET); while dopaminergic neurons have dopamine transporters (or DAT). These membrane proteins transport neurotransmitters from the synaptic cleft back into presynaptic neurons. This leads to a decreased neurotransmitter concentration within the synaptic cleft, causing the postsynaptic neurons to stop firing. Noradrenergic and serotonergic neurons are also rich in alpha 2 receptors. When stimulated, alpha 2 receptors inhibit the activity of the presynaptic neurons and decrease the release of norepinephrine or serotonin.

Now, in conditions such as major depressive disorder, atypical antidepressants are typically reserved for individuals that don’t respond to other antidepressants. Common medications in this group include mirtazapine, trazodone, nefazodone, vilazodone, vortioxetine, and bupropion. All right, first let’s start with mirtazapine. Mirtazapine binds and inhibits several receptors including alpha 2 receptors, 5-HT2A receptors, 5-HT3A receptors, and histamine H1 receptors. Its main antidepressant effect comes from the inhibition of alpha 2 receptors, which reduces the inhibition of the presynaptic neuron, leading to increased norepinephrine and serotonin release. Now mirtazapine is actually a serotonin antagonist, which might seem counterintuitive. But there are different types of 5-HT2 receptors; mirtazapine selectively blocks 5-HT2A and 5-HT3A receptors, so more serotonin can bind to 5-HT1A receptors; which have a stronger link to depression. Inhibition of 5-HT3A receptors also reduces nausea and vomiting. Lastly, inhibition of histamine H1 receptors leads to sedation, which could be desirable in depressed individuals with insomnia.

Other common side effects include dry mouth, increased appetite, and weight gain, which may be helpful for anorexic individuals. Next we have trazodone and nefazodone. These medications’ main antidepressant effect comes from their ability to bind 5-HT2A receptors, so more serotonin binds to 5-HT1A receptors. They are also weak inhibitors of serotonin reuptake transporters on the presynaptic neuron, thereby increasing the levels of serotonin within the synaptic cleft. They are strong H1 receptor inhibitors and are commonly used to treat insomnia. Finally they are also alpha 1 receptor inhibitors, which may cause orthostatic hypotension and priapism, which is a prolonged, unwanted erection of the penis. Nefazodone is also known to cause severe liver damage in rare cases.

Next we have vilazodone and vortioxetine, which are strong inhibitors of serotonin reuptake transporters on the presynaptic neuron just like SSRIs. However, these medications can also directly bind to and stimulate 5-HT1A receptors; vilazodone is a partial agonist, while vortioxetine is a full agonist. Since they enhance the effect of serotonin through 2 separate mechanisms, they can also cause serotonin syndrome, which is a life-threatening condition caused by serotonin accumulation and over stimulation of the nervous system. This syndrome is characterized by skin flushing, hyperthermia, agitation, muscle rigidity, seizure, and coma. It usually occurs in individuals treated with a combination of these medications and other antidepressants that increase serotonin levels, such as selective serotonin reuptake inhibitors. Treatment of serotonin syndrome consists of administration of cyproheptadine, which is a serotonin antagonist that blocks 5-HT2 receptors. These medications are anticholinergics and can cause atropine-like side effects such as sedation, blurred vision, orthostatic hypotension, urinary retention, and tachycardia. Vilazodone can also cause weight gain, while vortioxetine can cause abnormal dreams.

Key Takeaways

Atypical antidepressants are a class of antidepressant drugs that are distinguished from traditional, older antidepressant medications by their unique mechanism of action. They are generally reserved for cases that do not respond to other antidepressants. The atypical antidepressants include drugs like agomelatine, mirtazapine, and bupropion.

Atypical antidepressants are generally better tolerated than older drugs, and they are often just as effective. They are not without their side effects, however. The most common side effects of atypical antidepressants include nausea, headaches, anxiety, insomnia, and sexual dysfunction.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice" Rivista di Psichiatria (2019)
  5. "A review of trazodone use in psychiatric and medical conditions" Postgraduate Medicine (2016)
  6. "Bupropion Hydrochloride" Profiles of Drug Substances, Excipients and Related Methodology (2016)
  7. "Vortioxetine for depression in adults" Cochrane Database of Systematic Reviews (2017)
  8. "Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis" Journal of Affective Disorders (2018)